PUBLICATIONS

30.    Protocol to detect and quantify tumor hypoxia in mice using photoacoustic imaging

Dai T, Rich L, Seshadri M, Dasgupta S.

STAR Protocols (2024). 

29.    TRAF4-mediated nonproteolytic ubiquitination of androgen receptor promotes castration-resistant prostate cancer

Singh R, Meng H, Shen T, Lumahan LEV, Nguyen S, Shen H, Dasgupta S, Qin L, Karri D, Zhu B, Yang F, Coarfa C, O'Malley BW, Yi P   

PNAS- Proceedings of the National Academy of the Sciences U S A (2023).

28.    Regulation of tumor metabolism by post translational modifications on metabolic enzymes. 

Sawant Dessai A, Kalhotra P, Novickis AT, Dasgupta S.

Cancer Gene Therapy  (2023).

27.   Hypoxic activation of PFKFB4 in breast tumor microenvironment shapes metabolic and cellular plasticity to accentuate metastatic competence.

Dai, T, Spencer R; Katsuta, E; Paterson, EJ; Novickis, AT; Dessai, Abhisha Sawant; Gomez, Eduardo Cortes; Zhu, B; Liu, S; Wang, H; Abrams, SI, Seshadri, M, Bshara, W, Dasgupta, S.  

Cell Reports (2022).

26.    Optimization, and characterization of a bone culture model to study prostate cancer bone metastasis. 

Wu YH, Shen Y, Gugala Z, Dasgupta S, Wang H.  

Molecular Cancer Therapeutics  (2022).

25.    Low expression of miR-195 is associated with cell proliferation, glycolysis, and poor survival in estrogen receptor (ER)-positive but not   in triple negative breast cancer. 

Tokumaru Y, Oshi M, Patel A, Katsuta E, Yan L, Angarita FA, Dasgupta S, Nagahashi M, Matsuhashi N, Futamura M, Yoshida K, Takabe K. 

American Journal of Cancer Research  (2021).

24.    Steroid receptor coactivator 3 (SRC-3/AIB1) is enriched and functional in mouse and human Tregs. 

  Nikolai BC, Jain P, Cardenas DL, York B, Feng Q, McKenna NJ, Dasgupta S, Lonard DM, O'Malley BW. 

Science Reports  (2021).

23.    Transcriptional repression of SIRT3 potentiates mitochondrial aconitase activation to drive aggressive prostate cancer to the bone. 

Sawant Dessai A, Palestino Dominguez M, Chen U, Hasper J, Prechtl C, Yu C, Katsuta E, Dai T, Zhu B, Jung SY, Putluri N, Takabe K, Zhang XH, O’Malley BW, and Dasgupta S. 

Cancer Research (2021).

22.   High MYC mRNA expression is more clinically relevant than MYC DNA amplification in triple-negative breast cancer.

Katsuta E, Yan L, Takeshita T, McDonald K, Dasgupta S, Opyrchal M, Takabe K. 

International Journal of Molecular Sciences (2020).

21.     High expression of Annexin A2 is associated with DNA repair, metabolic alteration, and worse survival in pancreatic ductal         adenocarcinoma.  

Takahashi H, Katsuta E, Yan L, Dasgupta S, Takabe K.

Surgery (2019).

20.    Metabolic Dysregulation Controls Endocrine Therapy-Resistant Cancer Recurrence and Metastasis.

 Blundon MA and Dasgupta S.

 Endocrinology (2019).

19.     TRAF4- mediated NGF receptor TrkA ubiquitination regulates prostate cancer metastasis.

 Singh R, Karri D, Shao J, Dasgupta S, Huang S, Edwards D, O’Malley BW, and Yi P.

 Journal of Clinical Investigation (2018).

18.       Metabolic enzyme PFKFB4 activates oncogenic coactivator SRC-3 to drive breast cancer.

    Dasgupta S, Rajapakshe K, Zhu B, Nikolai BC, Yi P, Putluri N, Jung SY, Coarfa C, Westbrook TF, Zhang XH, Foulds CE, Tsai SY, Tsai MJ,                 O’Malley BW. 

    Nature (2018).

17.      Pathway- based integrative analysis reveals a key role for the hexosamine biosynthetic pathway in castration resistant prostate cancer       with therapeutic implications.

  Kaushik AK, Shojaie A, Panzitt K, Sonavane R, Venghatakrishnane R, Manikkam M, Zaslavskye A, Putluri V, Vasu V, Zhang Y, Lloyd S,               Szafran AT, Dasgupta S, et al.    

  Nature Communications (2016).

16.      HER2 signaling drives DNA anabolism and proliferation through SRC-3 phosphorylation and E2F1-regulated genes. 

    Nikolai BC, Lanz RB, York B, Dasgupta S, Mitsiades N, Creighton CJ, Tsimelzon A, Hilsenbeck SG, Lonard DM, Smith CL, O’Malley BW.

 Cancer Research (2016). 

15.    Coactivator-Dependent Oscillation of Chromatin Accessibility Dictates Circadian Gene Amplitude through REV-ERB Loading. 

 Zhu B, Stashi E, Gates LA, Dasgupta S, Gonzales N, Dean A, York B and O’Malley BW.

     Molecular Cell (2015). 

14.     A novel [15N] Glutamine Flux using LC- MS/MS-SRM for determination of nucleosides and nucleobases.

 Jin F, Bhowmik SK, Putluri1 V, Gu F, Gohlke G, Rundstedt FCV, Dasgupta S, Krishnapuram R, O’Malley BW, Sreekumar A and Putluri N.

 Journal of Analytical & Bioanalytical Techniques (2015).

13.      SRC-2 Orchestrates Polygenic Inputs for Fine-tuning Glucose Homeostasis. 

    Fleet T, Zhang B, Lin F, Zhu B, Dasgupta S, Stashi E, Tackett B, Thevananther S, Rajapakshe K, Gonzales N, Dean A, Mao J, Malovannaya        A, Qin J, Coarf C, DeMayo FJ, Dacso CC, Foulds CE, O’Malley BW and York B. 

 PNAS- Proceedings of the National Academy of the Sciences U S A (2015).

12.      MIEN1, a novel interactor of Annexin A2, promotes tumor cell migration and invasion by stimulating plasmin generation. 

            Kpetemey M*, Dasgupta S*, Rajendiran S, Das S, Shetty P, Gryczynski Z, and Vishwanatha JK.  * Co-first author

 Molecular Cancer (2015).  

11.      MIEN1 promotes oral cancer progression and implicates poor overall survival.

            Rajendiran S, Kpetemey M, Maji S, Gibbs LD, Dasgupta S, Mantsch R, Hare RJ, Vishwanatha JK. 

            Cancer Biology and Therapy (2015). 

10.     Coactivator SRC-2-dependent metabolic reprogramming mediates prostate cancer survival and metastasis. 

Dasgupta S, Putluri N, Long W, Kaushik AK, Zhang B, Bhowmik SK, Wang J, Stashi E, Brennan CA, Ittmann MM, Mitsiades N, Chinnaiyan AM, Sreekumar A, O’Malley BW. 

    Journal of Clinical Investigation (2015).

9.     Nuclear receptor coactivators: master regulators of human health and disease.

           Dasgupta S, Lonard DM, and O’Malley BW. 

          Annual Review of Medicine (2014).

8.       MicroRNA- 940 suppresses prostate cancer migration and invasion by regulating MIEN1. 

    Rajendiran S, Parwani AV, Hare RJ, Dasgupta S, R Rhonda K, Vishwanatha JK. 

    Molecular Cancer (2014).

7.       Transcriptional coregulators: emerging roles of SRC family of coactivators in disease pathology. 

          Dasgupta S and O'Malley BW. 

          Journal of Molecular Endocrinology (2014).

6.      SRC-2 is an essential coactivator for BMAL1:CLOCK in orchestrating circadian rhythm and metabolism. 

          Stashi E, Lanz B, Mao Z, Reineke LC, Kettner N, Stevenson C, Dasgupta S, Dean A, Sivasubramanian N, Reineke EL, York B, DeMayo FJ,          Fu L, and O’Malley BW. 

Cell Reports (2014).

5.      Oncogenic activation in prostate cancer progression and metastasis: molecular insights and future challenges. 

          Dasgupta S, Srinidhi S, and Vishwanatha JK. 

  Journal of Carcinogenesis (2012).

4.      Prenylated C17ORF37 induces filopodia formation to promote cell migration and metastasis.

 Dasgupta S, Cushman I, Kpetemey M, Casey PJ, and Vishwanatha JK. 

          Journal of Biological Chemistry (2012).

3.      Signal transducer and activator of transcription 6 (STAT6) is a novel interactor of Annexin A2 in prostate cancer cells. 

          Das S, Shetty P, Valapala M, Dasgupta S, Gryczynski Z, and Vishwanatha, J.K. 

          Biochemistry (2010).

2.     C17orf37 gene. 

        Dasgupta S and Vishwanatha JK. 

    Nature Molecule Pages (2009). 

1.      Novel gene C17orf37 in 17q12 amplicon promotes migration and invasion of prostate cancer cells. 

Dasgupta S, Wasson LM, Rauniyar N, Prokai L, Borejdo J, and Vishwanatha JK. 

         Oncogene (2009).